All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2023-11-10T15:05:41.000Z

Arterial and venous thromboembolic complication risks in patients with myeloproliferative neoplasms

Nov 10, 2023
Share:
Learning objective: After reading this article, readers will be able to cite the incidence and risk factors for arterial and venous thromboembolic complications in patients with myeloproliferative neoplasms.

Bookmark this article

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Arterial and venous thromboembolic (ATE/VTE) complications are more commonly observed in patients with myeloproliferative neoplasms (MPN) than in the general population and are associated with an increased risk of both mortality and morbidity. A study by Wille et al.1 examined the risk and incidence of ATE and VTE in patients with different MPN subtypes. The MPN Hub is pleased to summarize these findings here.

Study design1

This single-center retrospective study evaluated 832 patients with MPN for ATE/VTE complications.

ATE and VTE were shown to be associated with MPN if they occurred within two years before or following an MPN diagnosis.

Patient characteristics

At a median follow-up of 6.6 years, 180 patients experienced an ATE/VTE, with a 36.2% probability of a thromboembolic complication. The patient characteristics of the total cohort and those with a first complication are outlined in Table 1 and Table 2.

Table 1. Total cohort patient characteristics*

Characteristic, %

Total cohort
N = 832

Male

39.1

Female

60.9

MPN diagnosis

Essential thrombocytosis

31.7

Polycythemia vera

34.1

Myelofibrosis

31.1

Driver mutations

JAK2

69.8

CALR

14.4

MPL

2.5

Triple negative

5.2

Incomplete

8.1

ATE, arterial thromboembolism; CALR, calreticulin; JAK2, Janus kinase 2; MPL, myeloproliferative leukemia; MPN, myeloproliferative neoplasm; VTE, venous thromboembolism.
*Adapted from Wille, et al.1

Table 2. Patient characteristics if patients with a first complication*

Characteristic, %

Patients with thromboembolic complications
N
 = 180

Time of complication

              Prior to MPN diagnosis

32.2

              At the time of MPN diagnosis

17.2

              After MPN diagnosis

50.6

VTE

58.3

ATE

41.6

ATE, arterial thromboembolism; MPN, myeloproliferative neoplasm; VTE, venous thromboembolism.
*Adapted from Wille, et al.1

Results1

  • The incidence of VTE was higher than ATE, with 58.3% vs 41.6% of patients experiencing a thromboembolic complication, respectively.
  • The most common localizations of ATE were stroke, followed by transient ischemic attacks (Figure 1A).
  • The most common localization of VTE was deep vein thrombosis with or without pulmonary embolism, followed by splanchnic vein thrombosis (Figure 1B).

Figure 1. Localization and incidence of A ATE and B VTE*

ATE, arterial thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; TIA, transient ischemic attack; VT, vein thrombosis; VTE, venous thromboembolism.
*Data from Wille, et al.1

The cumulative incidence of ATE and VTE was comparable in the first year of follow-up. However, VTE became more common over time; at 20 years, the incidence of ATE and VTE was 0.122 and 0.18, respectively (Figure 2).

Figure 2. Cumulative incidence for ATE and VTE over time* 

ATE, arterial thromboembolism; CI, confidence interval; VTE, vein thromboembolism.
*Data from Wille, et al.1

When comparing factors associated with an increased risk of thromboembolic complications, differences were identified in both MPN subtype and mutational status (Figure 3).

  • A CALR and incomplete mutational status were associated with a significantly decreased risk compared with JAK2 mutation.
  • The polycythemia vera subtype was associated with a significantly increased risk compared with other MPN subtypes.

Figure 3. Risk factors associated with an increased risk of thromboembolic complications*†‡§ 

CALR, calreticulin; CI, confidence interval; MPL, myeloproliferative leukemia; MPN, myeloproliferative neoplasm.
*Data from Wille, et al.1
Values in bold are statistically significant.
Mutational status are compared with JAK2 mutation.
§
Polycythemia vera is compared with other MPN subtypes.

Conclusion

MPN are associated with a generally increased risk of VTE and ATE compared to a healthy population, with polycythemia vera posing the highest risk. Mutational status also influenced complications, and patients with CALR and incomplete mutational status were at a significantly decreased risk compared with other mutations, particularly the JAK2 mutated group.

  1. Wille K, Deventer E, Sadjadian P, et al. Arterial and venous thromboembolic complications in 832 patients with BCR-ABL-negative myeloproliferative neoplasms. Hamostaseologie. 2023. Online ahead of print. DOI: 1055/a-2159-8767

Your opinion matters

What do you consider to be the highest unmet need for patients with myelofibrosis?​
2 votes - 22 days left ...

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox